(Q45864886)

17 December 2017

title

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy (English)

1 reference

17 December 2017

1 reference

1 reference

Field JJ

1

1 reference

17 December 2017

Fenske TS

series ordinal

2

1 reference

17 December 2017

Blinder MA

series ordinal

3

1 reference

17 December 2017

publication date

1 January 2007

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

13

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

46-50

1 reference

17 December 2017

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Acquired high-titer factor VIII inhibitor: fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Rituximab-induced long-term remission in patients with refractory acquired hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Life-threatening bleeding from refractory acquired FVIII inhibitor successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

CD20: a target antigen for immunotherapy of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01342.X

10.1111/J.1365-2516.2006.01342.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017